Sinopharm Group Co. Ltd. (01099.HK) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	1143.8B	575.2B	584.5B	596.6B	552.1B
Cost of Revenue	1060.8B	533.5B	540.3B	548.1B	504.7B
Gross Profit	83.0B	41.7B	44.3B	48.5B	47.4B
Operating Expenses
R&D Expense	123.4M	—	—	—	—
SG&A Expense	48.1B	24.0B	25.6B	26.1B	24.9B
General & Admin Expense	11.9B	7.8B	8.4B	8.7B	8.2B
Selling & Marketing Expense	24.9B	16.2B	17.2B	17.5B	16.7B
Other Expenses	2.9B	1.6B	2.5B	2.2B	1.9B
Total Operating Expenses	51.1B	25.6B	28.1B	28.3B	26.8B
Cost and Expenses	1112.0B	559.1B	568.3B	576.4B	528.9B
Operating Income (EBIT)	31.9B	16.0B	16.2B	20.2B	20.6B
Non-Operating
Interest Income	922.6M	500.2M	617.0M	526.2M	542.8M
Interest Expense	3.8B	2.3B	2.7B	3.0B	3.5B
Net Interest Income	(3.4B)	(1.8B)	(2.1B)	(2.4B)	(3.0B)
Other Non-Op Income/Expense	(3.8B)	(1.2B)	(2.2B)	(697.1M)	(2.0B)
Non-Operating Income (excl Interest)	(3.0B)	(1.2B)	(1.6B)	(2.3B)	(1.5B)
EBT (Pre-Tax Income)	28.0B	14.8B	14.0B	19.5B	18.6B
Income Tax Expense	7.6B	4.0B	3.6B	4.5B	4.2B
Bottom Line
Net Income	13.8B	7.2B	7.0B	9.1B	8.5B
Earnings from Cont. Ops	20.5B	10.8B	10.4B	15.0B	14.3B
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	13.8B	7.2B	7.0B	9.1B	8.5B
Per Share
Basic EPS	HK$4.43	HK$2.29	HK$2.26	HK$2.90	HK$2.73
Diluted EPS	HK$4.43	HK$2.29	HK$2.26	HK$2.90	HK$2.73
Revenue Per Share	HK$366.55	HK$184.32	HK$187.31	HK$191.17	HK$176.93
Shares
Basic Shares Outstanding	3.1B	3.1B	3.1B	3.1B	3.1B
Diluted Shares Outstanding	3.1B	3.1B	3.1B	3.1B	3.1B
Profitability Metrics
EBITDA	41.2B	19.3B	20.2B	26.9B	26.2B
D&A	6.3B	2.0B	2.4B	4.4B	4.2B
EBIT	34.8B	17.2B	17.8B	22.5B	22.1B

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026